John Alexis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
John Alexis has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Akshay Bhandari
Division of Urology, Columbia University at Mount Sinai Medical Center, Miami Beach, Florida
1 shared publication - Alejandro Abello
Yale University School of Medicine, New Haven, CT, USA
1 shared publication - Brett Fukuma1 shared publication
- Hisham F. Bahmad
Department of Pathology and Laboratory Medicine, University of Miami Miller School of Medicine, Miami, FL 33136, USA
1 shared publication - Joan C. Delto
Department of Urology, Creighton University, School of Medicine, Omaha, Nebraska
1 shared publication - Kei Shing Oh
Arkadi M. Rywlin Department of Pathology and Laboratory Medicine Mount Sinai Medical Center Miami Beach Florida USA
1 shared publication
Latest Publications
- 27 April 2023
- Published by Wiley in Journal of Cutaneous Pathology
- Vol. 50 (8) , 763-772
Potential diagnostic utility of PRAME and p16 immunohistochemistry in melanocytic nevi and malignant melanoma
Background: PRAME (PReferentially expressed Antigen in MElanoma) is a tumor‐associated antigen that has been studied in various cutaneous melanocytic lesions. p16, on the other hand, has been proposed to aid in distinguishing between benign and malignant melanocytic neoplasms. Studies on the diagnostic utility of PRAME and p16 in combination in differentiating nevi from melanoma are limited. We aimed to assess the diagnostic utility of PRAME and p16 in melanocytic tumors and their role in distinguishing between malignant melanomas and melanocytic nevi.Methods: This is a single‐center retrospective cohort analysis over a 4‐year period (2017–2020). We used the pathological database of malignant melanomas (77 cases) and melanocytic nevi (51 cases) specimens from patients who underwent shave/punch biopsies or surgical excisions and evaluated immunohistochemical staining percentage positivity and intensity for PRAME and p16.Results: Most malignant melanomas showed positive/diffuse PRAME expression (89.6%); on the other hand, 96.1% of nevi did not express PRAME diffusely. p16 was expressed consistently in nevi (98.0%). However, p16 expression in malignant melanoma was infrequent in our study. PRAME had a sensitivity and specificity of 89.6% and 96.1%, respectively, for melanomas versus nevi; on the other hand, p16 had a sensitivity and specificity of 98.0% and 28.6%, respectively, for nevi versus melanoma. Also, a PRAME+/p16− melanocytic lesion is unlikely to be a nevus where most nevi were PRAME−/p16+.Conclusion: In conclusion, we confirm the potential utility of PRAME and p16 for distinguishing melanocytic nevi from malignant melanomas.
- 27 April 2023
- Published by Wiley in Journal of Cutaneous Pathology
- Vol. 50 (8) , 763-772
Potential diagnostic utility of PRAME and p16 immunohistochemistry in melanocytic nevi and malignant melanoma
Background: PRAME (PReferentially expressed Antigen in MElanoma) is a tumor‐associated antigen that has been studied in various cutaneous melanocytic lesions. p16, on the other hand, has been proposed to aid in distinguishing between benign and malignant melanocytic neoplasms. Studies on the diagnostic utility of PRAME and p16 in combination in differentiating nevi from melanoma are limited. We aimed to assess the diagnostic utility of PRAME and p16 in melanocytic tumors and their role in distinguishing between malignant melanomas and melanocytic nevi.Methods: This is a single‐center retrospective cohort analysis over a 4‐year period (2017–2020). We used the pathological database of malignant melanomas (77 cases) and melanocytic nevi (51 cases) specimens from patients who underwent shave/punch biopsies or surgical excisions and evaluated immunohistochemical staining percentage positivity and intensity for PRAME and p16.Results: Most malignant melanomas showed positive/diffuse PRAME expression (89.6%); on the other hand, 96.1% of nevi did not express PRAME diffusely. p16 was expressed consistently in nevi (98.0%). However, p16 expression in malignant melanoma was infrequent in our study. PRAME had a sensitivity and specificity of 89.6% and 96.1%, respectively, for melanomas versus nevi; on the other hand, p16 had a sensitivity and specificity of 98.0% and 28.6%, respectively, for nevi versus melanoma. Also, a PRAME+/p16− melanocytic lesion is unlikely to be a nevus where most nevi were PRAME−/p16+.Conclusion: In conclusion, we confirm the potential utility of PRAME and p16 for distinguishing melanocytic nevi from malignant melanomas.
- 1 September 2018
- Published by Galenos Yayinevi in Journal of Urological Surgery
- Vol. 5 (3) , 200-202
Multifocal Synchronous Chromophobe, Papillary, and Clear Cell Renal Cell Carcinoma in a Single Kidney
- 1 September 2018
- Published by Galenos Yayinevi in Journal of Urological Surgery
- Vol. 5 (3) , 200-202
Multifocal Synchronous Chromophobe, Papillary, and Clear Cell Renal Cell Carcinoma in a Single Kidney